Last €2.86 EUR
Change Today -0.065 / -2.22%
Volume 25.0
4QK On Other Exchanges
As of 9:37 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (4QK) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/29/15 - €2.95
52 Week Low
05/27/14 - €0.93
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CODEXIS INC (4QK)

codexis inc (4QK) Related Businessweek News

View More BusinessWeek News

codexis inc (4QK) Details

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

125 Employees
Last Reported Date: 03/13/14
Founded in 2002

codexis inc (4QK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.0K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $334.8K
Compensation as of Fiscal Year 2013.

codexis inc (4QK) Key Developments

Codexis, Inc. Develops Novel Enzyme Therapeutic Product Candidate for the Potential Treatment of Phenylketonuria

Codexis, Inc. announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) through oral administration. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. As a result, phenylalanine accumulates in high levels in the brain causing serious neurological problems, including intellectual disability, seizures and cognitive and behavioral problems. Phenylalanine is found in many foods, including meat, dairy products, fish, poultry and many fruits and vegetables. Codexis has conducted studies in a PKU animal model that demonstrate proof of concept for Codexis' therapeutic enzyme product candidate. In these studies, Codexis' enzyme therapeutic candidate was introduced into the stomach of the animal resulting in decreased blood phenylalanine levels. Codexis has filed patent applications covering the composition of matter for its therapeutic enzymes and the use of these enzymes as a treatment for PKU. Codexis is seeking partners for its PKU program to advance its development. Codexis expects to begin preclinical studies for its enzyme therapeutic candidate in 2015.

Codexis Seeks Partners For Its PKU Program

Codexis, Inc. (NasdaqGS:CDXS) is seeking partners for its PKU program to advance its development.

Codexis, Inc. Presents at LD Micro Conference, Dec-04-2014 12:30 PM

Codexis, Inc. Presents at LD Micro Conference, Dec-04-2014 12:30 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4QK:GR €2.86 EUR -0.065

4QK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cambrex Corp $22.06 USD -0.41
Koninklijke DSM NV €47.18 EUR +0.53
Novozymes A/S kr297.10 DKK -1.70
Takasago International Corp ¥586.00 JPY -3.00
View Industry Companies

Industry Analysis


Industry Average

Valuation 4QK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at